Department of Developmental Biomedicine, Gastroenterology Section, University of Bari, Bari, Italy.
Pediatrics. 2010 Dec;126(6):e1445-52. doi: 10.1542/peds.2010-0467. Epub 2010 Nov 15.
Our aim was to determine whether Lactobacillus rhamnosus GG (LGG) relieves symptoms in children with recurrent abdominal pain.
A total of 141 children with irritable bowel syndrome (IBS) or functional pain were enrolled in 9 primary care sites and a referral center. Children entered a randomized, double-blind, placebo-controlled trial and received LGG or placebo for 8 weeks and entered follow-up for 8 weeks. The primary outcome was overall pain at the end of the intervention period. At entry and at the end of the trial, children underwent a double-sugar intestinal permeability test.
Compared with baseline, LGG, but not placebo, caused a significant reduction of both frequency (P < .01) and severity (P < .01) of abdominal pain. These differences still were significant at the end of follow-up (P < .02 and P < .001, respectively). At week 12, treatment success was achieved in 48 children in the LGG group compared with 37 children in the placebo group (P < .03); this difference still was present at the end of follow-up (P < .03). At entry, 59% of the children had abnormal results from the intestinal permeability test; LGG, but not placebo, determined a significant decrease in the number of patients with abnormal results from the intestinal permeability testing (P < .03). These effects mainly were in children with IBS.
LGG significantly reduces the frequency and severity of abdominal pain in children with IBS; this effect is sustained and may be secondary to improvement of the gut barrier.
本研究旨在确定鼠李糖乳杆菌 GG（LGG）是否可缓解儿童反复发作性腹痛的症状。
共有 141 例患有肠易激综合征（IBS）或功能性腹痛的儿童在 9 个初级保健点和一个转诊中心入组。儿童入组一项随机、双盲、安慰剂对照试验，接受 LGG 或安慰剂治疗 8 周，并进行 8 周的随访。主要终点是干预期末的总体腹痛。在入组时和试验结束时，儿童接受双糖肠通透性试验。
与基线相比，LGG 而非安慰剂可显著减少腹痛的频率（P<.01）和严重程度（P<.01）。这些差异在随访结束时仍具有显著性（P<.02 和 P<.001）。在第 12 周时，LGG 组中有 48 例儿童治疗成功，而安慰剂组中有 37 例儿童（P<.03）；在随访结束时仍存在差异（P<.03）。入组时，59%的儿童肠通透性试验结果异常；LGG 而非安慰剂可显著减少肠通透性试验异常的患者人数（P<.03）。这些作用主要见于 IBS 儿童。
LGG 可显著减少 IBS 儿童腹痛的频率和严重程度；这种作用是持续的，可能与改善肠道屏障有关。
